Showing 3731-3740 of 5646 results for "".
- Ocugen Completes Dosing of Subjects with Stargardt Disease in Cohort 2 of Phase 1/2 GARDian Clinical Trial of OCU410ST Gene Therapyhttps://modernod.com/news/ocugen-completes-dosing-of-subjects-with-stargardt-disease-in-cohort-2-of-phase-12-gardian-clinical-trial-of-ocu410st-gene-therapy/2482280/Ocugen announced that dosing is complete in the second cohort of its phase 1/2 GARDian clinical trial for OCU410ST (AAV-hRORA)—a modifier gene therapy candidate being developed for Stargardt disease as a one-time treatment. "The completion of dosing for Cohort 2 par
- Arcscan's Insight 100 Ophthalmic Ultrasound Imaging System Approved in Chinahttps://modernod.com/news/arcscans-insight-100-ophthalmic-ultrasound-imaging-system-approved-in-china/2482279/ArcScan announced that the ArcScan Insight 100 has received National Medical Products Administration (NMPA) approval in China. The Insight 100 is designed to allow eye surgeons to more accurately determine the appropriate sizing of phakic IOLs for placement behi
- Beyeonics Vision Installs First Beyeonics ONE Digital Exoscopehttps://modernod.com/news/beyeonics-vision-installs-first-beyeonics-one-digital-exoscope/2482278/Beyeonics Vision announced it has installed the first Beyeonics ONE Digital Exoscope at Largo Ambulatory Surgery Center & Eye Institute of West Florida. According to Beyeonics Vision, the Beyeonics ONE Digital Exoscope is designed to enhance precision a
- Participants of Experimental CRISPR Gene Editing Trial See Vision Improvehttps://modernod.com/news/participants-of-experimental-crispr-gene-editing-trial-see-vision-improve/2482277/About 79% of clinical trial participants experienced measurable improvement after receiving experimental, CRISPR-based gene editing that is designed to fix a rare form of blindness, according to a paper published in the New England Journal of Medicine, the National Eye Institut
- Humonix Biosciences Appoints Karen Torrejon, PhD, as New CEOhttps://modernod.com/news/humonix-biosciences-appoints-karen-torrejon-phd-as-new-ceo/2482275/Humonix Biosciences announced the appointment of Karen Torrejon, PhD, as the new Chief Executive Officer. Dr. Torrejon, who originally founded the company in 2014, will now be leading the company as it transitions into a broader, science-driven platform. Humonix’s platform has bee
- Alcon to Acquire Israel-Based Belkin Vision, Maker of Eagle SLT Laserhttps://modernod.com/news/alcon-to-acquire-israel-based-belkin-vision-maker-of-eagle-slt-laser/2482270/Alcon has bolstered its glaucoma surgical portfolio after announcing plans to acquire Belkin Vision in deal potentially worth more than $300 million. The deal, which was first reported by Israel-based business news provider, Globes, has been confirmed by Eyewire+. According
- Annexon Presents New Neuroprotection Data Showing ANX007 Protects Vision and Vision-Associated Structures in GAhttps://modernod.com/news/annexon-presents-new-neuroprotection-data-showing-anx007-protects-vision-and-vision-associated-structures-in-ga/2482268/Annexon presented new analyses of ANX007 from the phase 2 ARCHER trial in geographic atrophy (GA), and new preclinical data on the role of C1q in the pathogenic elimination of photoreceptor synapses and their protection with C1q blockade in GA. ANX007 is a first-in-class, non-pegylated
- EyePoint Fails to Reach Primary Efficacy Endpoint in Phase 2 Trial of Duravyu in NPDRhttps://modernod.com/news/eyepoint-fails-to-reach-primary-efficacy-endpoint-in-phase-2-trial-of-duravyu-in-npdr/2482265/EyePoint Pharmaceuticals announced topline results of its phase 2 PAVIA clinical trial evaluating Duravyu (vorolanib intravitreal insert), previously known as EYP-1901, in patients with non-proliferative diabetic retinopathy (NPDR). In the trial, Duravyu did not meet the pre-specified p
- Ora Inc. and Singapore Eye Research Institute Announce Partnershiphttps://modernod.com/news/ora-and-singapore-eye-research-institute-unveil-partnership-to-propel-ophthalmology-innovation-globally/2482264/Contract Research Organization (CRO) Ora Inc. announced a partnership with the Singapore Eye Research Institute (SERI) that aims to provide early-stage innovators with comprehensive research support. Financial terms of the deal were not disclosed.
- Lumibird Launches C.DIAG Dry Eye Diagnostic Aid Platformhttps://modernod.com/news/lumibird-launches-cdiag-dry-eye-diagnostic-aid-platform-platform/2482260/Lumibird Medical announced the launch of the C.DIAG, a new-generation dry eye diagnostic aid platform with integrated AI algorithms. This new component of the C.SUITE is designed to enable healthcare professionals to diagnose, treat and educate dry eye patients. &ldq